Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Genitourinary Cancers
•
Thoracic Malignancies
•
Medical Oncology
•
Brain Metastases
•
Renal Cell Carcinoma
•
Non-small cell lung cancer
Would you offer systemic therapy after rendered NED from SRS to isolated CNS metastases in a patient with prior curative intent treatment of lung adenocarcinoma and clear cell RCC?
Related Questions
How do you approach treatment selection among novel bispecific antibodies and ADCs for patients with EGFR+ NSCLC previously treated with 3rd generation EGFR inhibitors?
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
What are your top takeaways in Thoracic Cancers from ASCO 2025?
Given potential long-term CV toxicity concerns with lorlatinib and data suggesting that dose reduction does not compromise efficacy, do you ever recommend initiating and/or maintaining lower-dose lorlatinib in ALK+ NSCLC?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
Are you planning to start running IHC HER2 testing on all tumor types, even those where HER2 overexpression is less typical, in light of tumor agnostic approval of trastuzumab deruxtecan?
When, if at all, do you utilize neoadjuvant chemotherapy alone for resectable, Stage II NSCLC with mutations such as EGFR or ALK?
In light of the 2024 Shkreli Awards, how do you address patient concerns regarding the 240 mg versus 960 mg dose of sotorasib?
When do you recommend incorporating HER2 testing into the diagnostic pathway for tumor types where HER2 overexpression is not commonly assessed?
